Literature DB >> 24636398

Nonobese diabetic/severe combined immunodeficient murine xenograft model for human uterine leiomyoma.

Guiwen Wang1, Hiroshi Ishikawa2, Kunizui Sone1, Tatsuya Kobayashi1, J Julie Kim3, Takeshi Kurita3, Makio Shozu1.   

Abstract

OBJECTIVE: To establish a novel xenograft model using a severely immunocompromised host that is more convenient for uterine leiomyoma research compared with a pre-existing model using nonobese diabetic/severe combined immunodeficient (NOD/SCID) IL-2Rγ-null mice.
DESIGN: Experimental study.
SETTING: University and an attached animal facility. ANIMAL(S): NOD/SCID, SCID, BALB/c nude, and NOD/SCID IL-2Rγ-null mice. INTERVENTION(S): Xenografts consisting of primary cultured leiomyoma and myometrial cells in the subrenal and subcutaneous (SC) spaces in ovariectomized mice, followed by sex steroids (estrogen and P) administration. MAIN OUTCOME MEASURE(S): Viability, volume, histology, and sex steroid receptor expression of xenografts in response to sex steroid administration, to evaluate feasibility of the model; and messenger RNA expression levels of 12 genes representative of leiomyoma in the xenografts, to characterize the model. RESULT(S): Leiomyoma xenografts increased in volume at the highest frequency (55.1%) in response to sex steroids in NOD/SCID mice. Xenografts reproduced the histology and maintained expression of sex steroids receptors and representative genes of the original tissues. Subrenal xenografts were significantly larger than the SC xenografts, whereas those consisting of myometrial cells never increased. CONCLUSION(S): The modified NOD/SCID murine subrenal leiomyoma xenograft model reproduced most characteristics of the original leiomyoma tissue. Our model provides a more convenient research tool to investigate the pathogenesis of uterine leiomyoma.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Leiomyoma; NOD/SCID; animal model; xenograft

Mesh:

Substances:

Year:  2014        PMID: 24636398     DOI: 10.1016/j.fertnstert.2014.01.054

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Cellular kinetics of MED12-mutant uterine leiomyoma growth and regression in vivo.

Authors:  Vanida A Serna; Xin Wu; Wenan Qiang; Justin Thomas; Michael L Blumenfeld; Takeshi Kurita
Journal:  Endocr Relat Cancer       Date:  2018-04-26       Impact factor: 5.678

2.  Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma.

Authors:  Xin Wu; Vanida A Serna; Justin Thomas; Wenan Qiang; Michael L Blumenfeld; Takeshi Kurita
Journal:  Cancer Res       Date:  2017-10-20       Impact factor: 12.701

3.  Patient-derived xenograft model for uterine leiomyoma by sub-renal capsule grafting.

Authors:  Vanida Ann Serna; Takeshi Kurita
Journal:  J Biol Methods       Date:  2018-04-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.